MetaCap

Coherus Oncology (CHRS) vs OKYO Pharma (OKYO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

OKYO Pharma (OKYO) has outperformed Coherus Oncology (CHRS) over the past year, losing 49.5% versus a loss of 68.1%. Coherus Oncology is the larger company by market cap ($57.1 million vs $56.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CHRS-68.12%OKYO-49.53%
+126%+24%-77%
Nov 21, 20251 yearNov 20, 2026
CHRS-95.55%OKYO-64.33%
+74%-15%-104%
May 16, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CHRS versus OKYO key metrics
MetricCHRSOKYO
Share price$0.3698$1.07
Market cap$57.15M$56.15M
1-day change-4.47%-7.76%
YTD return-73.96%-48.31%
1-year return-68.12%-49.53%
5-year return-97.99%—
EPS (TTM)$-1.12$-0.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$42.17M—
Revenue growth (YoY)+59.81%—
Net income (latest FY)$168.02M$-4.71M
Gross margin67.24%—
Operating margin-429.51%—
Net margin398.43%—
52-week high$2.62$3.20
52-week low$0.3628$1.00
Distance from 52-week high-85.86%-66.56%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1995.73%+678.50%
Average volume1.80M143.41K
Shares outstanding154.54M52.48M
Employees1445
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OKYO has outperformed CHRS by 18.6 percentage points over the past year.

About Coherus Oncology

CHRS stock →

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees

About OKYO Pharma

OKYO stock →

OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees

CHRS vs OKYO FAQ

Which is bigger, Coherus Oncology or OKYO Pharma?

Coherus Oncology (CHRS) is larger, with a market capitalization of $57.15M compared with $56.15M for OKYO Pharma (OKYO).

Which stock has performed better over the past year, CHRS or OKYO?

OKYO returned -49.53% over the past 12 months, compared with -68.12% for CHRS (price return, excluding dividends). Past performance does not predict future results.

Are Coherus Oncology and OKYO Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons